On 30 August 2011, orphan designation (EU/3/11/895) was granted by the European Commission to Susan French, United Kingdom, for hydroxy-propyl-beta-cyclodextrin for the treatment of Niemann-Pick disease, type C.
The sponsorship was transferred to Medical Need Europe AB, Sweden, in March 2015.
For a list of the administrative updates to this public summary of opinion please refer to the PDF document below.
The sponsorship was transferred to Alan Boyd Consultants Ltd, United Kingdom, in September 2018.
The sponsorship was transferred to Boyd Consultants Limited, Ireland, in March 2019.
The sponsor's address was updated in September 2021.
Treatment of Niemann-Pick's disease, type C
|Orphan designation status||
|EU designation number||
|Date of designation||
Review of designation
Documents related to this orphan designation evaluation
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.
EU register of orphan medicines
The list of medicines that have received an orphan designation in the EU is available on the European Commission's website: